Lloyd Marcea Bland 4

Accession 0001264124-12-000197

CIK 0000881464other

View on SEC.gov Company Profile

Filed

Aug 9, 8:00 PM ET

Accepted

Aug 10, 6:38 PM ET

Size

42.1 KB

Accession

0001264124-12-000197

Insider Transaction Report

Form 4

Period: 2012-08-08

AMYLIN PHARMACEUTICALS INCAMLN

Lloyd Marcea Bland

Sr VP Legal & Corp Affairs & G

Transactions

Other
Common Stock
2012-08-08$31.00/sh−1,160.6$35,979→ 0 total(indirect: By 401(k))
Expiration (Short)
Incentive Stock Option (right to buy)
2012-08-08$31.00/sh−9,352$289,912→ 0 total
Exercise: $41.27Exp: 2017-02-07→ Common Stock (9,352 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−79,954$2,478,574→ 0 total
Exercise: $9.02Exp: 2016-03-04→ Common Stock (79,954 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−101,035$3,132,085→ 0 total
Exercise: $16.02Exp: 2019-03-06→ Common Stock (101,035 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−53,669$1,663,739→ 0 total
Exercise: $18.01Exp: 2017-02-02→ Common Stock (53,669 underlying)
Other
Common Stock
2012-08-08$31.00/sh−1,360$42,160→ 0.4 total(indirect: by ESOP)
Other
Incentive Stock Option (right to buy)
2012-08-08$31.00/sh−5,046$156,426→ 0 total
Exercise: $9.02Exp: 2016-03-04→ Common Stock (5,046 underlying)
Other
Incentive Stock Option (right to buy)
2012-08-08$31.00/sh−8,965$277,915→ 0 total
Exercise: $16.02Exp: 2019-03-06→ Common Stock (8,965 underlying)
Other
Common Stock
2012-08-08$31.00/sh−926.2$28,712→ 1,160.6 total(indirect: By 401(k))
Other
Incentive Stock Option (right to buy)
2012-08-08$31.00/sh−6,331$196,261→ 0 total
Exercise: $18.01Exp: 2017-02-02→ Common Stock (6,331 underlying)
Expiration (Short)
Non-Qualified Stock Option (right to buy)
2012-08-08−40,648→ 0 total
Exercise: $41.27Exp: 2017-02-07→ Common Stock (40,648 underlying)
Other
Common Stock
2012-08-08$31.00/sh−412$12,772→ 0 total
Other
Common Stock
2012-08-08$31.00/sh−6,614$205,034→ 1,360.4 total(indirect: by ESOP)
Other
Common Stock
2012-08-08$31.00/sh−0.4$12→ 0 total(indirect: by ESOP)
Other
Incentive Stock Option (right to buy)
2012-08-08$31.00/sh−4,001$124,031→ 0 total
Exercise: $24.87Exp: 2015-03-04→ Common Stock (4,001 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−52,593$1,630,383→ 0 total
Exercise: $15.03Exp: 2018-03-01→ Common Stock (52,593 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−50,999$1,580,969→ 0 total
Exercise: $24.87Exp: 2015-03-04→ Common Stock (50,999 underlying)
Other
Common Stock
2012-08-08$31.00/sh−62,057.4$1,923,779→ 412 total
Other
Incentive Stock Option (right to buy)
2012-08-08$31.00/sh−7,407$229,617→ 0 total
Exercise: $15.03Exp: 2018-03-01→ Common Stock (7,407 underlying)
Other
Performance Shares
2012-08-08$31.00/sh−40,000$1,240,000→ 0 total
→ Common Stock (40,000 underlying)

Footnotes (5)

[F1]Represents a sale of shares to B&R Acquisition Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, either through directly tendering such shares or by virtue of a sale in the merger pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc. Includes unvested restricted stock units that were cancelled at the effective time of the merger in exchange for the right to receive cash payment for such restricted stock units at a price of $31.00 per restricted stock unit.
[F2]Represents a sale of shares to B&R Acquisition Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, either through directly tendering such shares or by virtue of a sale in the merger pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc.
[F3]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., these options, whether or not vested, were cancelled at the effective time of the merger in exchange for the right to receive cash payment in the amount of $31.00 per option less the exercise price of such option.
[F4]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., all options held by the reporting person with an exercise price above $31.00 per share were cancelled upon consummation of the merger.
[F5]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., these performance-based restricted stock units, whether or not vested, were canceled prior to consummation of the merger in exchange for the right to receive cash payment for each such restricted stock unit at a price of $31.00 per restricted stock unit.

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT

Issuer

AMYLIN PHARMACEUTICALS INC

CIK 0000881464

→

Entity typeother

Related Parties

filerCIK 0001389208

Filing Metadata

Form type: 4
Filed: Aug 9, 8:00 PM ET
Accepted: Aug 10, 6:38 PM ET
Size: 42.1 KB

View on SEC.gov